AQP4 and neuromyelitis optica: One area of recent progress is the immunosuppressive approach to block the onset of neuromyelitis optica by a combination of methods based on anti-AQP4 antibody binding to pathogenic autoantibodies and screening of blockers of the autoantibody-AQP4 interaction (Verkman et al., 2013).